Free tool
FAERS Monitor: Ganirelix Acetate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021057 or its brand name (Ganirelix Acetate, Ganirelix Acetate). Reports on generic versions are filed under their own applications.
Reports
719
Serious
327
45% of reports
Hospitalization
245
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- ovarian hyperstimulation syndrome225
- needle issue48
- ascites44
- nausea44
- no adverse event40
- poor quality device used40
- headache36
- injection site pain34
- drug ineffective31
- dyspnoea29
- fatigue29
- product quality issue28
- abdominal distension27
- abdominal pain27
- maternal exposure during pregnancy22
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 20 |
| 2014 | 48 |
| 2015 | 2 |
| 2016 | 8 |
| 2017 | 4 |
| 2018 | 24 |
| 2019 | 51 |
| 2020 | 31 |
| 2021 | 45 |
| 2022 | 114 |
| 2023 | 58 |
| 2024 | 101 |
| 2025 | 68 |
| 2026 | 143 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,440 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ovarian hyperstimulation syndromeSignal | 225 | 3125.4 | 2781.9 | 632,239 |
| poor quality device usedSignal | 40 | 117.1 | 86.6 | 4,473 |
| needle issueSignal | 48 | 48.3 | 36.7 | 2,176 |
| ascitesSignal | 44 | 43.8 | 32.9 | 1,799 |
| abdominal distensionSignal | 27 | 7.6 | 5.2 | 148 |
| maternal exposure during pregnancySignal | 22 | 7.2 | 4.8 | 112 |
| no adverse eventSignal | 40 | 6.5 | 4.8 | 181 |
| product quality issueSignal | 28 | 6.0 | 4.2 | 113 |
| abdominal painSignal | 27 | 3.4 | 2.3 | 44 |
| injection site painSignal | 34 | 3.2 | 2.3 | 51 |
| headache | 36 | 1.7 | 1.2 | 10 |
| nausea | 44 | 1.6 | 1.2 | 10 |
| dyspnoea | 29 | 1.5 | 1.0 | 4 |
| fatigue | 29 | 1.1 | 0.8 | 0 |
| drug ineffective | 31 | 0.7 | 0.5 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.